Suspended

Treatment of Anemia in Patients With Cancer Who Are Not Currently Receiving Chemotherapy or Radiotherapy

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Data Collection

Who is being recruted

Anemia

+ Hematologic Diseases
Over 18 Years
See all eligibility criteria
How is the trial designed

Treatment Study

Phase 3
Interventional
Study Start: February 2004
See protocol details

Summary

Principal SponsorJohnson & Johnson Pharmaceutical Research & Development, L.L.C.
Last updated: January 18, 2026
Sourced from a government-validated database.Claim as a partner
Study start date: February 1, 2004Actual date on which the first participant was enrolled.

The purpose of this study is to determine the effectiveness of different doses of epoetin alfa for treating anemia in patients who have cancer; or patients who no longer have any signs of cancer, but remain anemic as a result of their treatment. These patients should not be currently receiving chemotherapy or radiotherapy. A subject's participation in the study will last approximately 6 months. Subjects will receive weekly doses of epoetin alfa or placebo. Their hemoglobin will be tested every week.

Official TitleTreatment of Anemia in Patients With Cancer Who Are Not Currently Receiving Chemotherapy or Radiotherapy 
NCT00083486
Principal SponsorJohnson & Johnson Pharmaceutical Research & Development, L.L.C.
Last updated: January 18, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Treatment Study
These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria
Any sexBiological sex of participants that are eligible to enroll.
Over 18 YearsRange of ages for which participants are eligible to join.
Healthy volunteers not allowedIf individuals who are healthy and do not have the condition being studied can participate.
Conditions
Pathology
Anemia
Hematologic Diseases
Criteria

Inclusion Criteria: * Body weight \>/=99 lbs * ECOG 0-2 * Anemia results from cancer, chemotherapy, radiotherapy or an association with hormonal therapy or immunotherapy * Screening hemoglobin level of \</=11.0 g/dL for men or \</=10.0 for women

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.
This study has 12 locations
Suspended
Heritage Physician Group-OncologyHot Springs, United StatesSee the location
Suspended
Spalding Oncology ServicesGriffin, United States
Suspended
Southern Illinois HematologyCentralia, United States
Suspended
BioLab ResearchRockville, United States
Suspended12 Study Centers